Skip to main content
Erschienen in: Annals of Hematology 9/2009

01.09.2009 | Letter to the Editor

Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma

verfasst von: Adrian Tempescul, Jean-Christophe Ianotto, Frederic Morel, Veronique Marion, Marc De Braekeleer, Christian Berthou

Erschienen in: Annals of Hematology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36(2):115–127 (review)PubMed Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. Semin Hematol 36(2):115–127 (review)PubMed
3.
Zurück zum Zitat Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83(3):758–766PubMed Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83(3):758–766PubMed
4.
Zurück zum Zitat Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, Banchereau J, Liu YJ (1996) −Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 183(1):227–236. doi:10.1084/jem.183.1.227 PubMedCrossRef Merville P, Déchanet J, Desmoulière A, Durand I, de Bouteiller O, Garrone P, Banchereau J, Liu YJ (1996) −Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 183(1):227–236. doi:10.​1084/​jem.​183.​1.​227 PubMedCrossRef
5.
Zurück zum Zitat Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed
6.
Zurück zum Zitat Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47(7):1105–1114PubMed Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47(7):1105–1114PubMed
7.
Zurück zum Zitat Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104(8):2269–2271. doi:10.1182/blood-2004-03-1091 PubMedCrossRef Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104(8):2269–2271. doi:10.​1182/​blood-2004-03-1091 PubMedCrossRef
10.
Zurück zum Zitat Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B (2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140(3):313–319. doi:10.1111/j.1365-2141.2007.06937.x PubMedCrossRef Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B (2008) Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140(3):313–319. doi:10.​1111/​j.​1365-2141.​2007.​06937.​x PubMedCrossRef
11.
Zurück zum Zitat Wang M, Fayad L, Hegemeister F et al (2007) A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 25:8030 Wang M, Fayad L, Hegemeister F et al (2007) A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma with early evidence of efficacy. J Clin Oncol 25:8030
Metadaten
Titel
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma
verfasst von
Adrian Tempescul
Jean-Christophe Ianotto
Frederic Morel
Veronique Marion
Marc De Braekeleer
Christian Berthou
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 9/2009
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0692-4

Weitere Artikel der Ausgabe 9/2009

Annals of Hematology 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.